Background: As the most prevalent type of head and neck cancer, oral squamous-cell carcinoma (OSCC) accounts for nearly 90% of all oral cancer cases. Despite great progress having been made in the diagnosis and treatment of OSCC recently, the survival rate of OSCC patients has not risen remarkably. Chemotherapy is commonly used for OSCC treatment; however, the emergence of chemoresistance limits its long-term curative effect. Therefore, identifying effective biomarkers and molecular mechanisms is essential to the development of therapeutic strategies for OSCC.
Methods: qRT-PCR assays were performed to detect SNHG1  expression in OSCC tissue and cells, and CCK8 assays and animal experiments used to examine cell proliferation. In addition, CCK8 assays were used to detect IC ₅₀ values of cisplatin, 5Fu, Dox, and oncolytic adenovirus H101.
Results: We found that SNHG1  was overexpressed in OSCC tissue and cells and was associated with OSCC progression. In addition, knockdown of SNHG1  suppressed cell proliferation in vitro and in vivo. Importantly, we found that oncolytic adenovirus H101 showed better antitumor effects in OSCC with high SNHG1  expression, and chemotherapy showed worse anti-tumor effects in OSCC with high SNHG1  expression.
Conclusion: SNHG1  can act as a diagnostic biomarker for OSCC, and may be a biomarker for treatment options.
Keywords: SNHG1 , H101, OSCC